The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

With patents ... Vertex's push beyond CF, where years of investment are finally bearing fruit. All eyes are on Jan. 30, when the FDA weighs in on suzetrigine -- a potential game-changer for pain ...

A new type of painkiller aimed at treating pain from an injury or surgery has been approved by the US Food and Drug Administration (FDA). The drug suzetrigine, also known by its brand name Journavx, ...

A new type of painkiller aimed at treating pain from an injury or surgery has been approved by the US Food and Drug Administration (FDA). The drug suzetrigine, also known by its brand name Journavx, ...

Sooner or later, every successful drugmaker will face a "patent cliff ... d have more than enough left to scoop up a share of Vertex Pharmaceuticals (NASDAQ: VRTX). The big biotech stock currently ...

Even as Merck faces a patent cliff for Keytruda in 2028 ... One drug Chancellor said he’ll be keeping an eye on is Vertex Pharmaceuticals’ newly-approved cystic fibrosis treatment, Alyftrek, which ...

CarbonAi Inc. and Greenplinth Africa Limited are pleased to announce that they have entered into an agreement under which CarbonAi will provide its software tools to support the digital measurement, ...